EHP.L Share News (EHP)
EHP Share
EHP Share
EHP Share
EHP Share
EHP
EHP Share
EHP Broker
EHP Directors
EHP Financial
EHP
EHP Short
EHP
Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share. The new ordinary shares, which represent 8.9% of Epistem's issued share capital have been conditionally placed with existing and new i
Read moreInvestec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine. Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%. Earlier this month it reported steady full-year results, while d
Read moreBiotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes. Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine d
Read moreEpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts. The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis usin
Read moreBiotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for Indi
Read moreEpistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year. Revenue in the year to June 30th edged up to £5.75m from £5.74m the year before, while profit on ordinary activities before ta
Read moreAdult stem cell specialist Epistem scraped into profit in the first half of its financial year. The company, which made its maiden full year profit last year, saw profit before tax in the six months to the end of December rise to £0.1m from £5,000 in the corresponding period of 2009. Revenue rose
Read moreUK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007. The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all di
Read moreBlinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in
Read moreLONDON (Dow Jones)--Epistem Holdings PLC (EHP.LN), a biotechnology company, said Thursday that trading over the year was in line with market forecasts and the company expects to report growth in year on year after tax profit. -Shares closed Wednesday at 360 pence, valuing the company at GBP28.36
Read moreThe Novel Therapies division is threatening to steal the show at epithelial stem cells specialist Epistem, as the benefits of its transformational deal with Swiss pharmaceutical giant Novartis kicks in. The UK biotechnology company saw revenue soar 90% in 2009 almost entirely as a result of the co
Read moreOil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn
Read moreShares in stockbroker Shore Capital have almost tripled in value since April, but non-executive director Barclay Douglas thinks there's more to come. The accountant has spent £92,000 on 250,000 shares at 36.75p each. He now owns 1.25m shares, or half a per cent of the company. Shore received a sho
Read moreDrug testing group Epistem moved closer to profit after a research and collaboration deal with the Swiss pharmaceutical giant Novartis helped revenues soar. The firm posted a pre-tax loss of £700,000 in the year to June 30 compared with losses of £1.3m previously, with revenues nearly doubling to £
Read more